Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.46 |
| ▸ | PI4KA | P42356 | 5/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.36 |
| ▸ | TEK | Q02763 | 3/20 | 0.35 |
| ▸ | FLT1 | P17948 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Methyladenine SCHEMBL18229771 | 0.78 | ADORA2A (0.34) | ADORA2AADORA1 | |
| 3-Methyladenine SCHEMBL18229772 | 0.78 | PI4KA (0.35) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| 3-Propyladenine SCHEMBL15756434 | 0.76 | ADORA2A (0.53) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL6674435 | 0.75 | ADORA2A (0.33) | ADORA2AADORA1YTHDC1 | |
| SCHEMBL17371772 | 0.75 | — | — | |
| SCHEMBL1882911 | 0.75 | — | — | |
| SCHEMBL19522164 | 0.75 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| 3-Ethyladenine SCHEMBL48200 | 0.75 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL15974909 | 0.75 | ADORA2A (0.31) | ADORA2AADORA1 | |
| SCHEMBL9108201 | 0.72 | ADORA2A (0.36) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5744 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075438-A | Synergistic anticancer application of redox responsive coacervate delivery chrysin and 3-methyladenine | — | 2026-05-26 | — | — | CN | claimed |
| EP-4297723-B1 | MICRONEEDLE COMPOSITIONS AND METHODS OF DELIVERY USING THE SAME | BRIGHAM & WOMENS HOSPITAL INC (US) | 2026-05-20 | — | — | EP | claimed |
| US-12630851-B2 | Polynucleotide modification methods | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-19 | — | — | US | claimed |
| US-20260098287-A1 | METHOD AND KIT FOR REGENERATING REUSABLE INITIATORS FOR NUCLEIC ACID SYNTHESIS | CHENG-YAO CHEN (TW) | 2026-04-09 | — | — | US | claimed |
| US-20250369027-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | TWIST BIOSCIENCE CORP (US) | 2025-12-04 | — | — | US | claimed |
| US-12478685-B2 | Methods and kits for identifying subjects responsive to arginine deprivation therapy | POLARIS PHARMACEUTICALS. INC. (US) | 2025-11-25 | — | — | US | claimed |
| US-12458630-B2 | Combination therapy for cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-04 | — | — | US | claimed |
| US-20250327068-A1 | Method for Generation of a Nucleic Acid Library | MILTENYI BIOTEC BV & CO KG (DE) | 2025-10-23 | — | — | US | claimed |
| EP-4618997-A1 | COMPOSITIONS AND METHODS FOR IMPROVED CANCER TREATMENT | The Council of the Queensland Institute of Medical Research (AU) | 2025-09-24 | — | — | EP | claimed |
| WO-1999025385-A1 | A METHOD OF INCREASING NUCLEIC ACID SYNTHESIS WITH ULTRASOUND | IMARX PHARMACEUTICAL CORP. (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1998041648-A9 | TARGET GENES FOR ALLELE-SPECIFIC DRUGS | — | 1999-01-07 | — | — | WO | claimed |
| WO-1998041648-A2 | TARGET GENES FOR ALLELE-SPECIFIC DRUGS | VARIAGENICS, INC. (US) | 1998-09-24 | — | — | WO | claimed |
| WO-1998039334-A1 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-09-11 | — | — | WO | claimed |
| US-5659348-A | APPLYING TO A SUBSTRATE | XEROX CORPORATION (US) | 1997-08-19 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673783-A2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |